
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd Inc. recently bolstered its financial position by closing a public offering that raised $57.5 million, providing essential funding for its ongoing clinical programs. The company’s Phase 1/2 ‘extreme-dose’ safety trials have instilled high confidence in the long-term efficacy of its antibody candidates, particularly in providing robust protection against evolving viral threats. Additionally, the anticipated REVOLUTION launch is viewed as a significant milestone, reinforcing both regulatory and commercial prospects for Invivyd's innovative solutions in infectious disease management.
Bears say
Invivyd Inc. has experienced downward adjustments to its market share expectations, particularly regarding PEMGARDA in immunocompromised patient segments, leading to reduced price targets from $3.00 to $1.00 largely due to capital raise dilution. The company's reliance on the premise of enhanced, engineered immunity faces skepticism, particularly as it attempts to address concerns over current vaccine limitations such as waning antibody responses and public hesitancy. Additionally, the projected $4 billion revenue from COVID vaccine sales in 2024 highlights a competitive landscape, which may limit Invivyd's ability to capture significant market share amid doubts surrounding its product candidates.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares